BioSpace News Archive

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced two oral presentations that were made related to its lead candidate, FYARRO™ at the Connective Tissue Oncology Society 2021 Annual Meeting, held virtually from November 10-13, 2021.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced clinical data for lifileucel in combination with pembrolizumab in patients with advanced cancers were presented in an oral session at the Society for Immunotherapy of Cancer Annual Meeting.

Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that do not require gene editing and co-opt the natural biology of T cells to treat patients with solid tumors, announced the presentation of preclinical data from its proof-of-concept study in gastric cancer.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced six-month interim data from the “Durasert® and Vorolanib in Ophthalmology” Phase 1 clinical trial of EYP-1901, a bioerodible sustained delivery intravitreal anti-vascular endothelial growth factor treatment targeting wet age-related macular degeneration.

CG Oncology, Inc., a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for patients with advanced cancer, announced preliminary Phase 2 study results for CG0070 in combination with KEYTRUDA®, for the treatment of patients with Non-Muscle-Invasive Bladder Cancer unresponsive to Bacillus Calmette-Guerin.

NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer annual meeting in Washington, D.C., and on a virtual platform.

NewAmsterdam Pharma, a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases, announced full results from its Phase 2 Randomized Study of Obicetrapib as an Adjunct to Statin Therapy.

Veracyte, Inc. announced that new data from three posters were presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, highlighting the company’s immuno-oncology offerings for biopharmaceutical and academic researchers.

Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announces the presentation of interim Phase 1 data for BDB001 in combination with atezolizumab in advanced solid tumors at the 2021 Society for Immunotherapy of Cancer Annual Meeting.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announced the Company made two presentations on novel lead asset, INT230-6, at the Society for Immunotherapy of Cancer’s 36th Annual Meeting in Washington, D.C.